Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Management of Postradical Prostatectomy Urinary Incontinence: A Review.

Radadia KD, Farber NJ, Shinder B, Polotti CF, Milas LJ, Tunuguntla HSGR.

Urology. 2018 Mar;113:13-19. doi: 10.1016/j.urology.2017.09.025. Epub 2017 Oct 12. Review.

PMID:
29031841
2.

Inhibition of P-TEFb by DRB suppresses SIRT1/CK2╬▒ pathway and enhances radiosensitivity of human cancer cells.

Wang ZQ, Johnson CL, Kumar A, Molkentine DP, Molkentine JM, Rabin T, Mason KA, Milas L, Raju U.

Anticancer Res. 2014 Dec;34(12):6981-9.

PMID:
25503124
3.

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.

Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK.

Radiother Oncol. 2012 Nov;105(2):241-9. doi: 10.1016/j.radonc.2012.08.010. Epub 2012 Sep 23.

PMID:
23010482
4.

The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation.

Matsumoto F, Valdecanas DN, Mason KA, Milas L, Ang KK, Raju U.

Anticancer Res. 2012 Aug;32(8):3029-35.

PMID:
22843870
5.

Mitigation and treatment of radiation-induced thoracic injury with a cyclooxygenase-2 inhibitor, celecoxib.

Hunter NR, Valdecanas D, Liao Z, Milas L, Thames HD, Mason KA.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):472-6. doi: 10.1016/j.ijrobp.2012.04.025. Epub 2012 Jun 5.

PMID:
22672748
6.

Poly (ADP-ribose) polymerase inhibitors in cancer treatment.

Mason KA, Raju U, Buchholz TA, Wang L, Milas ZL, Milas L.

Am J Clin Oncol. 2014 Feb;37(1):90-100. doi: 10.1097/COC.0b013e3182467dce. Review.

PMID:
22495455
7.

Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.

Sano D, Berlin JM, Pham TT, Marcano DC, Valdecanas DR, Zhou G, Milas L, Myers JN, Tour JM.

ACS Nano. 2012 Mar 27;6(3):2497-505. doi: 10.1021/nn204885f. Epub 2012 Feb 16.

8.

MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.

Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C, Milas L.

Invest New Drugs. 2012 Dec;30(6):2113-20. doi: 10.1007/s10637-011-9770-x. Epub 2011 Nov 30.

PMID:
22127459
9.

Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells.

Wang L, Raju U, Milas L, Molkentine D, Zhang Z, Yang P, Cohen L, Meng Z, Liao Z.

Anticancer Res. 2011 Jun;31(6):2141-8.

PMID:
21737634
10.

Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.

Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN.

Clin Cancer Res. 2011 Apr 1;17(7):1815-27. doi: 10.1158/1078-0432.CCR-10-2120. Epub 2011 Feb 24.

11.

Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.

Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR Jr, Kies MS.

Front Oncol. 2011 Dec 13;1:52. doi: 10.3389/fonc.2011.00052. eCollection 2011.

12.

Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.

Riesterer O, Yang Q, Raju U, Torres M, Molkentine D, Patel N, Valdecanas D, Milas L, Ang KK.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1179-87. doi: 10.1016/j.ijrobp.2010.10.003. Epub 2010 Dec 2.

13.

Are cancer stem cells radioresistant?

Hittelman WN, Liao Y, Wang L, Milas L.

Future Oncol. 2010 Oct;6(10):1563-76. doi: 10.2217/fon.10.121. Review.

14.

Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.

Skvortsova I, Skvortsov S, Raju U, Stasyk T, Riesterer O, Schottdorf EM, Popper BA, Schiestl B, Eichberger P, Debbage P, Neher A, Bonn GK, Huber LA, Milas L, Lukas P.

Radiother Oncol. 2010 Jul;96(1):108-15. doi: 10.1016/j.radonc.2010.04.017. Epub 2010 May 5.

PMID:
20451273
15.

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.

Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK.

Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2.

PMID:
20119866
16.

Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.

Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U.

Anticancer Res. 2009 Nov;29(11):4409-15.

17.

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Riesterer O, Matsumoto F, Wang L, Pickett J, Molkentine D, Giri U, Milas L, Raju U.

Invest New Drugs. 2011 Jun;29(3):514-22. doi: 10.1007/s10637-009-9361-2. Epub 2009 Dec 22.

PMID:
20024691
18.

Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.

Riesterer O, Mason KA, Raju U, Yang Q, Wang L, Hittelman WN, Ang KK, Milas L.

Radiother Oncol. 2009 Sep;92(3):383-7. doi: 10.1016/j.radonc.2009.07.009. Epub 2009 Aug 18.

PMID:
19695723
19.

Receptor signaling as a regulatory mechanism of DNA repair.

Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK.

Radiother Oncol. 2009 Sep;92(3):316-22. doi: 10.1016/j.radonc.2009.06.031. Epub 2009 Jul 15. Review.

20.

Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.

Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1580-91. doi: 10.1016/j.ijrobp.2009.03.047. Epub 2009 Jun 17.

PMID:
19540073
21.

Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.

Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q.

J Clin Oncol. 2009 Jul 10;27(20):3370-8. doi: 10.1200/JCO.2008.20.6763. Epub 2009 Apr 20.

22.

The role of apoptosis in radiation oncology.

Meyn RE, Milas L, Ang KK.

Int J Radiat Biol. 2009 Feb;85(2):107-15. doi: 10.1080/09553000802662595. Review.

PMID:
19280463
23.

Cancer stem cells and tumor response to therapy: current problems and future prospects.

Milas L, Hittelman WN.

Semin Radiat Oncol. 2009 Apr;19(2):96-105. doi: 10.1016/j.semradonc.2008.11.004. Review.

PMID:
19249647
24.

Combining molecular therapeutics with radiotherapy for head and neck cancer.

Riesterer O, Milas L, Ang KK.

J Surg Oncol. 2008 Jun 15;97(8):708-11. doi: 10.1002/jso.21011. Review.

PMID:
18493923
25.

Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.

Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):203-12. Epub 2007 Nov 8.

PMID:
17996386
26.

Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Thariat J, Milas L, Ang KK.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):974-84. Review. No abstract available.

27.

Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.

Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, J├╝rgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1534-43. Epub 2007 Sep 24.

28.

Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.

Riesterer O, Milas L, Ang KK.

J Clin Oncol. 2007 Sep 10;25(26):4075-83. Review.

PMID:
17827456
29.

Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer.

Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C.

Oncol Rep. 2007 Sep;18(3):645-51.

PMID:
17671714
30.

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Mason KA, Valdecanas D, Hunter NR, Milas L.

Invest New Drugs. 2008 Feb;26(1):1-5. Epub 2007 Jul 13.

PMID:
17628743
31.

Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide.

Wiedenmann N, Koto M, Raju U, Milas L, Mason KA.

Invest New Drugs. 2007 Oct;25(5):411-6. Epub 2007 May 11.

PMID:
17492397
32.

Combination of radiotherapy with EGFR antagonists for head and neck carcinoma.

Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK.

Int J Clin Oncol. 2007 Apr;12(2):99-110. Epub 2007 Apr 27. Review.

PMID:
17443277
33.

Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?

Liao Z, Mason KA, Milas L.

Drugs. 2007;67(6):821-45. Review.

PMID:
17428102
34.

130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.

Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA.

Clin Cancer Res. 2007 Mar 15;13(6):1868-74.

35.

Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.

Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):870-8.

36.

Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation.

Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):568-72.

PMID:
17236972
37.

CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.

Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L.

Radiother Oncol. 2006 Aug;80(2):192-8. Epub 2006 Aug 14.

PMID:
16905212
38.

Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.

Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L.

Radiother Oncol. 2006 Aug;80(2):185-91. Epub 2006 Aug 14.

PMID:
16905211
39.

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.

Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS.

Clin Cancer Res. 2006 Aug 1;12(15):4590-7.

40.

Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.

Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H.

Am J Clin Oncol. 2006 Aug;29(4):376-9.

PMID:
16891865
41.

S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.

Nakata E, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, Nakamura Y, Milas L, Yamada S.

Oncol Rep. 2006 Sep;16(3):465-71.

PMID:
16865244
42.

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA.

J Clin Oncol. 2006 Aug 10;24(23):3789-98. Epub 2006 Jun 19.

PMID:
16785472
43.

Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.

Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G, Selzer E, Verheij M, Hendry JH.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):551-61.

PMID:
16414371
44.

Targeting molecular determinants of tumor chemo-radioresistance.

Milas L, Raju U, Liao Z, Ajani J.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81. Review.

PMID:
16399438
45.

Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.

Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):520-8.

PMID:
16168844
46.

Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.

Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR.

Semin Oncol. 2005 Apr;32(2 Suppl 3):S92-8.

PMID:
16015542
47.

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase.

Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, Rodemann HP.

J Biol Chem. 2005 Sep 2;280(35):31182-9. Epub 2005 Jul 5.

48.

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.

Clin Cancer Res. 2005 May 1;11(9):3342-8.

49.

Selective radioprotection of normal tissues by Bowman-birk proteinase inhibitor (BBI) in mice.

Dittmann K, Toulany M, Classen J, Heinrich V, Milas L, Rodemann HP.

Strahlenther Onkol. 2005 Mar;181(3):191-6.

PMID:
15756524
50.

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.

Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L.

Clin Cancer Res. 2005 Jan 1;11(1):361-9.

Supplemental Content

Support Center